When viewed in terms of performance, the ENZC performance for the week was 37.63% while its performance for the month was 44.25%. The quarterly performance of Enzolytics, Inc. (OTC PINK:ENZC) saw a decline of -1.17%, and 9.94% for the last six months. In the last 52 weeks, the stock’s price range has been $0.0047–$0.9580. Nothing new appeared in the publications about the stock. In fact, the most recent news about the stock was almost 2 months ago.

Most Recent News

On July 29, 2021, ENZC revealed that an agreement was reached with Danhson and Clinic Design to advance Enzolytics’ anti-HIV therapeutic ITV-1 into production and clinical trials. Prior to approval by the European Medicines Agency (EMA), these steps were necessary.

It was revealed in an announcement that the Clinical trials will be conducted at Clinic Design after production of the therapeutic is completed at Danhson pharmaceutical company facilities. Then the production of the therapeutics will be completed followed by clinical trials. In this trial, Pharmalex, an EU regulatory consulting firm, will be in charge of developing the protocol.

July 26, 2020– Enzolytics, Inc. (OTC PINK:ENZC) announced Steve Sharabura has been appointed as President of its Atlanta-based wholly-owned subsidiary RobustoMed, Inc. The Atlanta-based subsidiary was to develop a new business model focused on establishing international partnerships with drug development companies. The focus of Mr. Sharabura’s work was on expanding revenue and partnerships in key markets globally, including Brazil, Costa Rica, and other emerging markets.

Canadian native Mr. Sharabura also has international experience. A key United Nations agency relied on him for technology expansion. An emerging technology worth $10m plus has been sold to major telecommunications firms by him. Steve has worked in various technology fields for over 30 years, both with small entrepreneurial companies and large multinational corporations. In the past, he has improved company productivity across a wide range of fields.

The MBA he earned at Cornell University is combined with an undergraduate degree in economics from the University of Western Ontario.

What do they do at ENZC?

ENZC develops proprietary antibiotics that treat debilitating infectious diseases. We have patented HIV therapeutics and a proprietary method for producing human IgG1 monoclonal antibodies to treat infectious diseases without causing any harm to humans. Our HIV therapeutics have undergone clinical testing. The company has also created a proprietary cell line that can produce human monoclonal antibodies that neutralize HIV. The company is based in Plano, Texas.